Ionis Pharmaceuticals (NASDAQ:IONS) Given New $65.00 Price Target at Guggenheim

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) had its target price decreased by investment analysts at Guggenheim from $80.00 to $65.00 in a report issued on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Guggenheim‘s price objective indicates a potential upside of 141.10% from the company’s previous close.

IONS has been the subject of a number of other reports. Wells Fargo & Company reduced their price target on shares of Ionis Pharmaceuticals from $95.00 to $80.00 and set an “overweight” rating for the company in a research report on Tuesday, November 10th. The Goldman Sachs Group dropped their price objective on Ionis Pharmaceuticals from $58.00 to $41.00 and set a “neutral” rating on the stock in a report on Tuesday, November 10th. BMO Capital Markets raised Ionis Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $54.00 to $66.00 in a report on Thursday, October 22nd. Canaccord Genuity Group cut their target price on Ionis Pharmaceuticals from $95.00 to $85.00 and set a “buy” rating on the stock in a research report on Tuesday, September 8th. Finally, UBS Group initiated coverage on Ionis Pharmaceuticals in a report on Thursday, October 15th. They issued a “buy” rating and a $88.00 target price for the company. Nineteen research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $75.00.

Read Our Latest Research Report on IONS

Ionis Pharmaceuticals Stock Down 3.7%

Shares of NASDAQ:IONS opened at $26.96 on Wednesday. The firm has a 50 day simple moving average of $42.45 and a 200-day simple moving average of $64.02. Ionis Pharmaceuticals has a twelve month low of $26.55 and a twelve month high of $86.74. The company has a current ratio of 5.43, a quick ratio of 5.36 and a debt-to-equity ratio of 3.42. The company has a market capitalization of $4.49 billion, a PE ratio of -8.12 and a beta of 0.43.

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($1.23) by $0.57. The firm had revenue of $242.72 million for the quarter, compared to the consensus estimate of $178.17 million. Ionis Pharmaceuticals had a negative net margin of 56.98% and a negative return on equity of 120.62%. The company’s revenue was up 54.8% on a year-over-year basis. During the same period last year, the firm posted ($0.80) EPS. On average, equities analysts predict that Ionis Pharmaceuticals will post -3.57 EPS for the current fiscal year.

Insider Transactions at Ionis Pharmaceuticals

In related news, EVP Shannon L. Devers sold 1,357 shares of the firm’s stock in a transaction dated Friday, October 16th. The shares were sold at an average price of $43.54, for a total value of $59,083.78. Following the completion of the sale, the executive vice president owned 17,811 shares in the company, valued at $775,490.94. This trade represents a 7.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Michael R. Hayden acquired 5,000 shares of the stock in a transaction on Tuesday, November 10th. The stock was acquired at an average cost of $29.64 per share, for a total transaction of $148,200.00. Following the acquisition, the director directly owned 27,000 shares in the company, valued at $800,280. This represents a 22.73% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 1.81% of the company’s stock.

Hedge Funds Weigh In On Ionis Pharmaceuticals

A number of large investors have recently modified their holdings of the business. Integrated Wealth Concepts LLC grew its position in shares of Ionis Pharmaceuticals by 7.4% during the 2nd quarter. Integrated Wealth Concepts LLC now owns 2,926 shares of the company’s stock valued at $232,000 after buying an additional 202 shares during the last quarter. HighTower Advisors LLC raised its stake in Ionis Pharmaceuticals by 7.6% during the second quarter. HighTower Advisors LLC now owns 4,084 shares of the company’s stock worth $324,000 after acquiring an additional 287 shares during the period. Grandfield & Dodd LLC raised its stake in Ionis Pharmaceuticals by 0.9% during the third quarter. Grandfield & Dodd LLC now owns 37,396 shares of the company’s stock worth $1,670,000 after acquiring an additional 319 shares during the period. North Dakota State Investment Board lifted its holdings in Ionis Pharmaceuticals by 7.1% in the third quarter. North Dakota State Investment Board now owns 5,035 shares of the company’s stock worth $225,000 after acquiring an additional 332 shares during the last quarter. Finally, ProShare Advisors LLC lifted its holdings in Ionis Pharmaceuticals by 6.4% in the third quarter. ProShare Advisors LLC now owns 5,762 shares of the company’s stock worth $257,000 after acquiring an additional 345 shares during the last quarter. 93.86% of the stock is owned by hedge funds and other institutional investors.

About Ionis Pharmaceuticals

(Get Free Report)

Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.

See Also

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.